The U.S. Food and Drug Administration has granted full approval to Pfizer's Braftovi (encorafenib) as part of a combination regimen for treating metastatic colorectal cancer patients with BRAF V600E mutations. The approval encompasses use of the drug alongside cetuximab and fluorouracil-based chemotherapy, expanding treatment options for this patient population with a specific genetic mutation.
The FDA's decision was supported by efficacy and safety data from the Phase 3 BREAKWATER trial, which demonstrated meaningful clinical benefits for patients receiving the combination therapy. The trial showed improvements in both progression-free survival and overall survival compared to standard treatment approaches, establishing the regimen's clinical value in managing advanced colorectal cancer.
The approved therapy is currently under regulatory review in Europe and has already received marketing authorization in several additional countries. This regulatory milestone reinforces Pfizer's oncology portfolio and provides physicians with an additional option for treating the subset of colorectal cancer patients carrying BRAF V600E mutations, a molecular marker that typically characterizes a more aggressive disease subtype.